Skip to Main content Skip to Navigation
Journal articles

Stable prevalence of transmitted drug resistance mutations and increased circulation of non-B subtypes in antiretroviral-naive chronically HIV-infected patients in 2015/2016 in France

Lambert Assoumou 1, 2 Laurence Bocket 3 Coralie Pallier 4 Maxime Grude 1, 2 Rachid Ait-Namane 2, 1 Jacques Izopet 5 Stéphanie Raymond 5 Charlotte Charpentier 6, 7 Benoit Visseaux 6, 7 Marc Wirden 1, 8 Mary-Anne Trabaud 9 Hélène Le Guillou-Guillemette 10 Chakib Allaoui 11 Cécile Henquell 12 Anne Krivine 13 Georges dos Santos 14 Catherine Delamare 15 Magali Bouvier-Alias 16 Brigitte Montes 17 Virginie Ferré 18 Anne de Monte 19 Anne Signori-Schmuck 20 Anne Maillard 21 Laurence Morand-Joubert 22, 1, 23 Camille Tumiotto 24 Samira Fafi-Kremer 25 Corinne Amiel 26 Francis Barin 27 Stéphanie Marque-Juillet 28 Laurence Courdavault 29, 30 Sophie Vallet Agnès Beby-Defaux 31 Alexis de Rougemont 32 Honorine Fenaux 33 Véronique Avettand-Fenoël 34, 35 Annick Allardet-Servent 36 Jean-Christophe Plantier 37 Gilles Peytavin 38 Vincent Calvez 1, 8, 23 Marie-Laure Chaix 39 Diane Descamps 6, 7 
Abstract : Objectives: We estimated the prevalence of transmitted-drug-resistance-associated mutations (TDRAMs) in antiretroviral-naive chronically HIV-1-infected patients. Patients and methods: TDRAMs were sought in samples from 660 diagnosed HIV-1-infected individuals in 2015/2016 in 33 HIV clinical centres. Weighted analyses, considering the number of patients followed in each centre, were used to derive representative estimates of the percentage of individuals with TDRAMs. Results were compared with those of the 2010/2011 survey (n = 661) using the same methodology. Results: At inclusion, median CD4 cell counts and plasma HIV-1 RNA were 394 and 350/mm3 (P = 0.056) and 4.6 and 4.6 log10 copies/mL (P = 0.360) in the 2010/2011 survey and the 2015/2016 survey, respectively. The frequency of non-B subtypes increased from 42.9% in 2010/2011 to 54.8% in 2015/2016 (P < 0.001), including 23.4% and 30.6% of CRF02_AG (P = 0.004). The prevalence of virus with protease or reverse-transcriptase TDRAMs was 9.0% (95% CI = 6.8-11.2) in 2010/2011 and 10.8% (95% CI = 8.4-13.2) in 2015/2016 (P = 0.269). No significant increase was observed in integrase inhibitor TDRAMs (6.7% versus 9.2%, P = 0.146). Multivariable analysis showed that men infected with the B subtype were the group with the highest risk of being infected with a resistant virus compared with others (adjusted OR = 2.2, 95% CI = 1.3-3.9). Conclusions: In France in 2015/2016, the overall prevalence of TDRAMs was 10.8% and stable compared with 9.0% in the 2010/2011 survey. Non-B subtypes dramatically increased after 2010. Men infected with B subtype were the group with the highest risk of being infected with a resistant virus, highlighting the need to re-emphasize safe sex messages.
Complete list of metadata

https://hal-normandie-univ.archives-ouvertes.fr/hal-02154058
Contributor : Sandy Mzembaba Connect in order to contact the contributor
Submitted on : Wednesday, June 12, 2019 - 4:28:45 PM
Last modification on : Friday, September 9, 2022 - 10:20:08 AM

Identifiers

Citation

Lambert Assoumou, Laurence Bocket, Coralie Pallier, Maxime Grude, Rachid Ait-Namane, et al.. Stable prevalence of transmitted drug resistance mutations and increased circulation of non-B subtypes in antiretroviral-naive chronically HIV-infected patients in 2015/2016 in France. Journal of Antimicrobial Chemotherapy, Oxford University Press (OUP), 2019, 74 (5), pp.1417-1424. ⟨10.1093/jac/dkz011⟩. ⟨hal-02154058⟩

Share

Metrics

Record views

188